MedTrace Logo

SARS-CoV-2 Antibody Response in Children Aged 5-11 Years Following Vaccination Against COVID-19

NCT05175989 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2022-01-28

No results posted yet for this study

Summary

There are few data on the immunogenicity of the Pfizer-Biontec BNT162b2 vaccine for the prevention of COVID-19 disease and of side effects in children aged 5-11 years. Therefore, our aim is to determine the immunogenicity and to describe the local or systemic reactogenicity events after vaccination with the BNT162b2 COVID-19 vaccine in children aged 5-11 years for a period of six and half months following the first dose of the vaccine.

Conditions

  • COVID-19 Vaccine

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Eligibility

Min Age
5 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-10
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05175989 on ClinicalTrials.gov